Forbes September 11, 2023
The impact of the Inflation Reduction Act on the biopharmaceutical industry is going to be substantial in a number of ways. Already companies are analyzing the strategies for the types of programs that they work on in light of the coming price controls. For example, should less research be done in areas that lead to small molecule drugs (pills) given that such drugs will face price negotiations four years sooner than biologic drugs (given by infusion or intravenously)? While far more costly to deliver to patients, biologics offer the potential for higher financial returns due to longer price exclusivity.
Similarly, biopharma companies are revising clinical development plans for drugs that have a number of potential uses. In the past, companies...
Today's Sponsors
Today's Sponsor